These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20733125

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.
    Caponetti GC, Miranda RN, Althof PA, Dobesh RC, Sanger WG, Medeiros LJ, Greiner TC, Weisenburger DD.
    Hum Pathol; 2012 Dec; 43(12):2223-8. PubMed ID: 22748304
    [Abstract] [Full Text] [Related]

  • 24. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
    Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, Martinelli G.
    J Clin Oncol; 2006 Feb 01; 24(4):e6-7. PubMed ID: 16446324
    [No Abstract] [Full Text] [Related]

  • 25. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 01; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 26. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 01; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 27. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group.
    Endocr Relat Cancer; 2006 Jun 01; 13(2):535-40. PubMed ID: 16728580
    [Abstract] [Full Text] [Related]

  • 28. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 01; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 29. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 30. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.
    N Engl J Med; 2002 Aug 15; 347(7):481-7. PubMed ID: 12181402
    [Abstract] [Full Text] [Related]

  • 31. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.
    J Clin Oncol; 2005 Jan 20; 23(3):585-90. PubMed ID: 15659505
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
    Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S.
    J Clin Oncol; 2011 Jul 20; 29(21):2904-9. PubMed ID: 21690468
    [Abstract] [Full Text] [Related]

  • 35. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M, Demertzis N, Iakovidou I, Kottakis S.
    Anticancer Res; 2007 Jul 20; 27(2):1143-7. PubMed ID: 17465254
    [Abstract] [Full Text] [Related]

  • 36. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A.
    Nepal Med Coll J; 2007 Dec 20; 9(4):292. PubMed ID: 18298026
    [No Abstract] [Full Text] [Related]

  • 37. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
    Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, Brousse N, Piette JC.
    Blood; 2008 Jun 01; 111(11):5413-5. PubMed ID: 18502845
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.
    N Engl J Med; 2002 Aug 15; 347(7):472-80. PubMed ID: 12181401
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
    Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, Choi JG, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Shin SW, Yoon SY, Cho Y, Kim YK, Kim YH, Kim JS.
    Am J Hematol; 2004 Dec 15; 77(4):366-9. PubMed ID: 15551277
    [Abstract] [Full Text] [Related]

  • 40. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 15; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.